Anti-clot drug recommended for new approval in EU

September 21, 2012 by Linda A. Johnson

(AP)—Advisers to European Union regulators have recommended approval of a new anti-clotting drug for use by adults with a common irregular heart rhythm that boosts risk of strokes or blood clots, drugmakers Bristol-Myers Squibb Co. and Pfizer Inc. said.

The drug, Eliquis, is a crucial one for the two companies, which have been slammed by new generic competition slashing sales of their top-selling drugs. Meanwhile, the partners are trailing competitors in a three-way race for global market share in a new class of anti-clotting drugs expected to be blockbusters, with sales well over $1 billion a year.

Pfizer and Bristol-Myers, both based in New York, said Friday advisers to the European Medicines Agency have issued a positive opinion on Eliquis for use in patients with the irregular rhythm called atrial fibrillation if it's not caused by a heart valve problem. If the European Medicines Agency approves it, that would allow sales in all 27 European Union member states, as well as Iceland and Norway.

The drug got its first approval in May 2011, also in the EU, for treating a much smaller group of patients, adults who have had hip or knee replacement surgery.

However, the U.S. Food and Drug Administration has rejected the drug twice, most recently in June. The agency said it needed more information on "data management and verification" from a huge international study called ARISTOTLE, but the FDA did not require new studies. That would have delayed any potential approval for a couple of years.

Known chemically as apixaban, Eliquis is one of three new medicines heavily touted for preventing blood clots and the strokes and heart attacks they can trigger.

Boehringer Ingelheim's Pradaxa was approved for U.S. sales in late 2010. Xarelto, sold by Johnson & Johnson and Bayer Healthcare, was approved in November 2011.

The companies say this new generation of blood thinners works better than the long-time standard, warfarin.

Millions of patients and their doctors have long wanted a better alternative to warfarin, an inexpensive generic drug also sold under brand names such as Coumadin. Getting the dose of warfarin correct is so tricky that patients need frequent blood tests to ensure they're getting enough to prevent clots but not enough to cause internal bleeding. Some foods interact with warfarin, adding to the difficulty.

The newer drugs also carry risks of serious internal bleeding. They cost nearly twice the price for warfarin, including the cost of the blood tests that drug requires.

___

Linda A. Johnson can be followed at —twitter.com/LindaJ_onPharma

Explore further: J&J again seeks more approvals for clot blocker

shares

Related Stories

J&J again seeks more approvals for clot blocker

September 7, 2012
(AP)—Johnson & Johnson has given the Food and Drug Administration additional data to on its new anticlotting drug, in a second attempt to get approval for more uses.

Quick-reversal method may be at hand for new blood thinner

June 20, 2012
(HealthDay) -- Newer blood-thinning drugs sometimes have one drawback: In cases where they trigger bleeding, their effects can be tough to reverse compared to the standard anticoagulant, warfarin.

Bristol-Myers recalls vials of cancer drug

August 30, 2012
(AP)—Bristol-Myers Squibb Co. is recalling more than 31,000 units of a chemotherapy drug after discovering one vial was overfilled, putting patients at risk of an overdose.

FDA questions safety of experimental diabetes drug

July 15, 2011
(AP) -- Federal health regulators have concerns about bladder and breast cancer seen in patients taking an experimental diabetes pill from Bristol-Myers Squibb and AstraZeneca.

Bristol-Myers to buy diabetes drug maker for $5B

July 1, 2012
(AP) — Drug maker Bristol-Myers Squibb Co. says it agreed to buy diabetes drug maker Amylin Pharmaceuticals for about $5 billion in cash.

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.